Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.
Carlo Visco, MD, associate professor, Department of Medicine, Section of Hematology, University of Verona, Verona, Italy, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma (MCL).
The MANTLE-FIRST trial evaluated the outcomes of patients with MCL who had progressive disease or first relapse following treatment with high-dose cytarabine (HDAC) and autologous stem cell transplantation in eligible patients.
Although MCL remains a difficult-to-treat disease, the up-front treatment of patients is well established, Visco explains.
However, the second-line setting of MCL does not have a well-defined standard of care, and the majority of patients with MCL who go into remission will eventually relapse, says Visco. As such, establishing a standard of care regimen for patients who fail induction therapy remains an unmet need, Visco concludes.